Genmab (GMAB) Event May 11, 2022, 15:24 UTC (30% Negative) Genmab (GMAB) Reports Q2 2022 Financial Results (Form 6-K) Full text
Register to leave comments News bot Oct. 18, 2025, 4:51 p.m. 🌍 Genmab (GMAB) - Form 6-K Filing Filing Date: 2022-05-11 Accepted: 2022-05-11 11:24:41 Event Type: Financial Results Event Details: DARZALEX net sales as reported by Johnson Johnson increased 36% compared to the first three months of 2021 to USD 1,856 million. Genmab updates its 2022 financial guidance. First patient dosed with DuoBody-CD3xB7H4 (GEN1047) 📊 Key Financial Metrics (Year-over-Year Comparison): Metric 2022 2021 Change ($) Change (%) Revenue 2.12K 1.58K $538.00 +34.03% Operating Income 514.00 532.00 $-18.00 -3.38% Net Income 465.00 1.10K $-631.00 -57.57% Cash 9.07K 8.96K $114.00 +1.27% Assets 24.91K 24.63K $287.00 +1.17% Equity 22.72K 22.20K $523.00 +2.36% Liabilities 2.19K 2.43K $-236.00 -9.71% 💼 Business Developments: ✅ Partnership/Collaboration✅ Acquisition Activity✅ Licensing Agreement✅ Regulatory Milestone❌ Leadership Updates: Not reported 📞 Contact Information: Email: mmp@genmab.com
🌍 Genmab (GMAB) - Form 6-K Filing
Filing Date: 2022-05-11
Accepted: 2022-05-11 11:24:41
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
📞 Contact Information: